Research and Markets (http://www.researchandmarkets.com/research/qg6r3v/pharmahandbook)
has announced the addition of the "pharmahandbook:
Three Report Special Offer - BRIC/Asia Pacific/United States"
book to their offering.
Asia-Pacific 2013: 260-page report with what you need to know to succeed
in 8 key pharma markets with $300 billion in combined sales.
Intellectual property in India. PBS access in Australia. Generics in
Japan. And China. What about China? The pharmaceutical industry has
questions. Our Asia-Pacific report has answers. It contains the
information and analysis you need to expand or improve your drug
development and business prospects in 8 countries with 55% of the
world's population and $300 billion in combined pharmaceutical sales.
The world's second and third-largest markets, Japan and China, are
covered as are rapidly-developng India and Indonesia, newly-emerged
South Korea and Taiwan, and mature but still-evolving Australia and New
BRIC Report 2013: 175-pages packed with data and analysis on structural,
regulatory and commercial aspects in each of pharma's Big 4 emerging
markets: Brazil, Russia, India, and China.
Brazil, Russia, India, China. They share an acronym and rapid growth
rates but otherwise the Big 4 Emerging Markets don't have a lot in
common. With extensive data and analysis on the structural, regulatory
and commercial aspects of the biopharmaceutical markets in each country,
pharmahandbook's 2013 BRIC report provides you with what you need to
know in order to capitalize on these vitally important but complex and
United States 2013: 160-page report with in-depth coverage of virtually
every aspect of the world's largest pharmaceutical market. The most
thorough and incisive report on navigating the U.S. pharma market
$325 billion. That's the size of the U.S. pharmaceutical market. It
translates to one-third of global industry sales but achieving success
in the world's largest market is a lot tougher than it used to be.
That's where the latest U.S. pharmahandbook comes in. If you want to
understand how the Affordable Care Act will affect your sales, where the
brand and generic sectors will be in five years, what's happening with
biosimilars, how the pricing and reimbursement systems are changing, and
the real reason that pharmaceuticals sales have slowed (as well as what
you can do about it), look no further than U.S. pharmahandbook 2013.
Why you need it
The markets are essential for any pharmaceutical company that hopes to
grow its business over the next five years. This pharmahandbook report
shows you how to succeed in these important and challenging locations.
For more information visit http://www.researchandmarkets.com/research/qg6r3v/pharmahandbook
[ Back To NFVZone's Homepage ]